Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration (Q73098659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

L Patmore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S Fraser

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

D Mair

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Templeton

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

English

0 references

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Pharmacology

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

406

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

449-452

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Quinolone activity against anaerobes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Quinolone-induced QT interval prolongation: a not-so-unexpected class effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Effects of fluoroquinolones on HERG currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Torsades de pointe probably related to sparfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900694-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(00)00694-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11040352%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference